# MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

> **NCT03932253** · PHASE1 · SUSPENDED · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 79 (actual)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** FCN-159

## Key facts

- **NCT ID:** NCT03932253
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-03-21
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Sponsor R\&D strategy adjustment
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03932253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03932253, "MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03932253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*